Kirby Institute, UNSW, Sydney, Australia.
HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):489-497. doi: 10.1097/QAI.0000000000002464.
We validated the Data collection on Adverse events of anti-HIV Drugs (D:A:D) full-risk and short-risk score models for chronic kidney disease (CKD) in the Asian HIV cohorts.
A validation study among people living with HIV (PLHIV) aged ≥18 years among the cohorts in the Asia-Pacific region.
PLHIV with a baseline estimated glomerular filtration rate > 60 mL/min/1.73 m were included for validation of the D:A:D CKD full version and short version without cardiovascular risk factors. Those with <3 estimated glomerular filtration rate measurements from baseline or previous exposure to potentially nephrotoxic antiretrovirals were excluded. Kaplan-Meier methods were used to estimate the probability of CKD development. The area under the receiver operating characteristics was also used to validate the risk score.
We included 5701 participants in full model {median 8.1 [interquartile range (IQR) 4.8-10.9] years follow-up} and 9791 in short model validation [median 4.9 (IQR 2.5-7.3) years follow-up]. The crude incidence rate of CKD was 8.1 [95% confidence interval (CI): 7.3 to 8.9] per 1000 person-years in the full model cohort and 10.5 (95% CI: 9.6 to 11.4) per 1000 person-years in the short model cohort. The progression rates for CKD at 10 years in the full model cohort were 2.7%, 8.9%, and 26.1% for low-risk, medium-risk, and high-risk groups, and 3.5%, 11.7%, and 32.4% in the short model cohort. The area under the receiver operating characteristics for the full-risk and short-risk score was 0.81 (95% CI: 0.79 to 0.83) and 0.83 (95% CI: 0.81 to 0.85), respectively.
The D:A:D CKD full-risk and short-risk score performed well in predicting CKD events among Asian PLHIV. These risk prediction models may be useful to assist clinicians in identifying individuals at high risk of developing CKD.
我们在亚太地区的 HIV 队列中验证了针对抗 HIV 药物不良反应的 Data collection on Adverse events of anti-HIV Drugs (D:A:D) 全风险和短风险评分模型在慢性肾脏病(CKD)中的应用。
一项在年龄≥18 岁的 HIV 感染者(PLHIV)中进行的队列研究。
纳入基线估算肾小球滤过率(eGFR)>60 mL/min/1.73 m 的 PLHIV,用于验证不伴有心血管危险因素的 D:A:D CKD 全版本和短版本。排除基线时 eGFR 测量值<3 或以前接触过潜在肾毒性抗逆转录病毒药物的患者。采用 Kaplan-Meier 法估计 CKD 发生的概率。也使用受试者工作特征曲线下面积来验证风险评分。
我们纳入了 5701 名全模型参与者(中位随访 8.1 [四分位距(IQR)4.8-10.9]年)和 9791 名短模型验证参与者(中位随访 4.9 [IQR 2.5-7.3]年)。全模型队列的 CKD 粗发生率为 8.1 [95%置信区间(CI):7.3-8.9]/1000 人年,短模型队列为 10.5(95%CI:9.6-11.4)/1000 人年。全模型队列中 CKD 10 年的进展率为低危、中危和高危组分别为 2.7%、8.9%和 26.1%,短模型队列分别为 3.5%、11.7%和 32.4%。全风险和短风险评分的受试者工作特征曲线下面积分别为 0.81(95%CI:0.79-0.83)和 0.83(95%CI:0.81-0.85)。
D:A:D CKD 全风险和短风险评分模型在预测亚洲 PLHIV 的 CKD 事件方面表现良好。这些风险预测模型可能有助于临床医生识别发生 CKD 的高危个体。